Tegileridine

Tegileridine
Clinical data
Trade names	艾苏特
Legal status
Legal status	Rx in China;
Identifiers
	IUPAC name (1S,4S)-4-Ethoxy-N-[2-[(9R)-9-pyridin-2-yl-6-oxaspiro[4.5]decan-9-yl]ethyl]-1,2,3,4-tetrahydronaphthalen-1-amine;
CAS Number	2095345-66-5;
PubChem CID	129049969;
Chemical and physical data
Formula	C28H38N2O2
Molar mass	434.624 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCO[C@H]1CC[C@@H](C2=CC=CC=C12)NCC[C@]3(CCOC4(C3)CCCC4)C5=CC=CC=N5;
	InChI InChI=1S/C28H38N2O2/c1-2-31-25-13-12-24(22-9-3-4-10-23(22)25)29-19-16-27(26-11-5-8-18-30-26)17-20-32-28(21-27)14-6-7-15-28/h3-5,8-11,18,24-25,29H,2,6-7,12-17,19-21H2,1H3/t24-,25-,27+/m0/s1; Key:YUMLNLMFBWBKSK-OHSXHVKISA-N;

Tegileridine is a drug which acts as a μ-opioid receptor agonist. It is closely related to compounds such as oliceridine, TRV734, and SHR9352, and shares a similar profile as a biased agonist selective for activation of the G-protein signalling pathway over β-arrestin 2 recruitment.^[1]

In January 2024, tegileridine was approved in China for the treatment of moderate to severe pain after abdominal surgery.^[2]

References

^ WO 2017063509, "Oxa spiro derivative, preparation method therefor, and applications thereof in medicines", published 10 April 2018, assigned to Jiangsu Hengrui Medicine Company and Shanghai Hengrui Pharmaceutical Company Ltd .
^ Dhillon, Sohita (2024). "Tegileridine: First Approval". Drugs. doi:10.1007/s40265-024-02033-4.

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

[1] WO 2017063509, "Oxa spiro derivative, preparation method therefor, and applications thereof in medicines", published 10 April 2018, assigned to Jiangsu Hengrui Medicine Company and Shanghai Hengrui Pharmaceutical Company Ltd .

[2] Dhillon, Sohita (2024). "Tegileridine: First Approval". Drugs. doi:10.1007/s40265-024-02033-4.

[1]

[2]

See also

References